Leblond V, Aktan M, Coll CMF, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot J-L, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica 2018; 103(11):1889-1898; https://doi.org/10.3324/haematol.2017.186387.